Incyte Corporation
INCY US
INCY USIncyte Corporation
United States Composite53.76
Company Description
- CEO
- Mr. Herve Hoppenot
- Full Time Employees
- 2,524
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1801 Augustine Cut-Off Wilmington DE United States 19803
- IPO Date
- Nov 4, 1993
- CIK
- 0000879169
- Website
- www.incyte.com
- Business
- Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; and in-license agreements with Agenus, Merus, MacroGenics, and Syndax. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Company News
Incyte to Present at Upcoming Investor Conference
Incyte Corp (INCY) Q1 2024 Earnings Call Transcript Highlights: Strategic Acquisitions and Robust Revenue Growth
Q1 2024 Incyte Corp Earnings Call Transcript
Incyte Corp (INCY) Q1 2024 Earnings: Misses Revenue Estimates but Shows Strong Growth in Clinical Programs
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
The past three years for Incyte (NASDAQ:INCY) investors has not been profitable
Certain Biotech Investors Get an Early Look at Results. Is That Fair?
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
Novartis (NVS) to Undertake Job Cuts in Development Department
Incyte to Report First Quarter Financial Results
Incyte to Report First Quarter Financial Results
Agilent (A) is Set for Analytica 2024 With Advanced Products
Biotech Executive Who Bet on Rival’s Stock Committed Insider Trading, Jury Says
SEC Wins Novel ‘Shadow’ Insider Trading Trial Against Executive
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up
Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up
SEC Tests Insider-Trading Theory at Trial of Ex-Biotech Executive